Navigation Links
BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
Date:4/5/2011

RALEIGH, N.C., April 5, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today completion of enrollment in its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain.

(Logo: https://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

"The completion of enrollment in our Phase 3 efficacy study marks another very important milestone in our clinical development program for BEMA Buprenorphine in the management of chronic pain," stated Dr. Andrew Finn, Executive Vice President of Product Development at BDSI.  "We are very pleased to have achieved our aggressive recruitment and enrollment goals.  This milestone keeps us on target for reporting top-line study results in the third quarter of this year and is consistent with a timeline that would allow for a New Drug Application (NDA) to be filed in the second quarter of 2012."

BDSI believes that there remains a significant unmet medical need for potent new analgesics for the treatment of chronic pain.  The company believes that buprenorphine is an attractive option for development because of its potent analgesic properties, its differentiating characteristics from other opioids and its DEA Schedule III designation, which means there is less addiction potential than Schedule II products.  In addition, BEMA Buprenorphine has the potential to be the first oral transmucosal form of buprenorphine to treat chronic pain in the U.S.  According to Wolters Kluwer, opioid analgesic sales in the U.S. are in excess of $10 billion and growing, and BDSI believes that BEMA Buprenorphine has the potential to exceed $500 million in peak annual sales.

Additional Information on Phase 3 Study Design (BUP-301)

This Phase 3 trial of BEMA Buprenorphine (referred to as BUP-301) is
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
2. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
3. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
4. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
5. TCG Lifesciences Expands Pharmaceutical, Biotechnology Research Initiatives with CAS SciFinder®
6. Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
7. Caliper Life Sciences Launches Novel COX-2 Probe to Enable Personalized Medicine Research
8. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
9. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
10. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
11. Newborn Possibilities Fund Awards Grant to Georgia Health Sciences University Foundation to Support Groundbreaking Pediatric Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014  Eiger BioPharmaceuticals Incorporated announced the positive ... in patients with chronic hepatitis delta virus (HDV) ... Institutes of Health (NIH) Clinical Center in ... placebo-controlled, dose ascending study evaluated two doses of ... twice daily for 28 days.  "This proof-of-concept study ...
(Date:12/19/2014)... the Friday, December 19 edition of USA ... (HIT) features Konica Minolta, the company announced today. The supplement will ... healthcare organizations. In addition to the print section ... New York , Chicago , ... Minneapolis and San Francisco , ...
(Date:12/19/2014)... Dec. 19, 2014  Advanced Medical Isotope Corporation ... engaged primarily in the development of brachytherapy devices ... today announced that a Life Sciences Discovery Fund ... for which AMIC is the commercialization partner.  The ... for the proposal titled "Optimized Injectable Radiogels for ...
Breaking Medicine Technology:Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3
... 2007 /PRNewswire/ - Cytochroma Inc.,announced today positive data ... The initial top-line results from this trial,showed that ... are expected in August 2007. , The recently ... randomized study of CTA018 Injection,administered to 20 healthy ...
... PRINCETON, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - Cytogen,Corporation ... Phase 1,dose escalation study evaluating QUADRAMET(R) (samarium ... Pharmaceuticals, Inc.) in patients with relapsed,multiple myeloma. ... in a,poster titled, "Phase 1 Trial of ...
Cached Medicine Technology:Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 2Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8
(Date:12/22/2014)... OH (PRWEB) December 22, 2014 Explorys, ... three additions to its leadership team: Greg Yarrington as ... of Engineering, and Patrick Wells as Vice President of ... to add 80 new jobs in 2015 to support ... expansion of its platform-as-a-service offerings, and growth of its ...
(Date:12/22/2014)... CA (PRWEB) December 22, 2014 ... now offering consultations for sleep apnea. Drowsy drivers are ... than drivers who are well-rested, and some experts believe ... the roads as intoxicated drivers. Unfortunately, millions of Americans ... the American Academy of Sleep Medicine, about 18 million ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Christmas is days ... has a fast and easy solution that will please: the ... can be purchased from from $25 up to $350," says ... 100% customer satisfaction and a wide array of skin care ... fees and no expiration dates. , Gift delivery past ...
(Date:12/22/2014)... Washington, DC (PRWEB) December 22, 2014 ... Nursing Leadership Conference, next month in San ... strategies to address dynamics that often stand in ... authority, and competition. , This premier faculty ... Center for Transformational Leadership, whose mission is to ...
(Date:12/21/2014)... (PRWEB) December 22, 2014 BellasDress.com offers ... more for women. Today, it announces its BellasDress ... products at its online store. , BellasDress is a ... benefits to its fans through a series of promotions. ... for every customer. , “We are proud of ...
Breaking Medicine News(10 mins):Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 3Health News:BellasDress.com Announces its BellasDress Christmas Sale 2
... development by a team of researchers at the University of ... medical procedures. , The system works by using a Web-based ... children from the procedures that cause the pain. The distractions ... watching a video, talking, or playing a game. , The ...
... is proud to announce,that President and CEO Humberto ... Jury President for North America. Jury members for ... their,achievements in the business, non-profit and academic fields, ... The awards, an annual distinction supporting innovative woman-led,business ...
... to Brooke Army Medical Center, RESTON, Va., ... ), an information technology and network solutions (IT),company, ... competitive task order under,the US Army,s HRsolutions Indefinite ... and Support to provide,services to Brooke Army Medical ...
... Illinois at Chicago has been named one of 10 ... consumers and clinicians make critical treatment decisions about therapeutic ... of the Agency for Healthcare Research and Quality,s Center ... It will design and test systems to optimize drug ...
... Oct. 16 (HealthDay News) -- A new gene associated with ... Dmp1 gene may help improve understanding of what ... , The Wake Forest University School of Medicine researchers analyzed ... the Dmp1 gene -- which normally works to ...
... 16 Starpharma,Holdings Ltd (ASX: SPL, Pink Sheets: ... SSL International plc (LSE: SSL), owner of Durex(R), ... which a commercial licence will be negotiated,sets out ... coating.,Undisclosed fees are payable to Starpharma under the ...
Cached Medicine News:Health News:UI researchers seek to ease children's pain during medical procedures 2Health News:UI researchers seek to ease children's pain during medical procedures 3Health News:Galderma Associates Itself to Cartier's Women's Initiative Awards to Recognize Female Entrepreneurs From Around the Globe 2Health News:Galderma Associates Itself to Cartier's Women's Initiative Awards to Recognize Female Entrepreneurs From Around the Globe 3Health News:SI International Awarded $4 Million Army HRsolutions Task Order 2Health News:SI International Awarded $4 Million Army HRsolutions Task Order 3Health News:New UIC center to study drug choices, safety 2Health News:Researchers ID New Gene Linked to Lung Cancer 2Health News:Starpharma and Durex Sign Co-Development Agreement for VivaGel(R)-Coated Condoms 2
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Wide scleral bed. Outside diameter 30.2 mm....
...
...
...
Medicine Products: